MX2009000654A - Medios para inhibir la expresion de la cinasa de proteina 3. - Google Patents
Medios para inhibir la expresion de la cinasa de proteina 3.Info
- Publication number
- MX2009000654A MX2009000654A MX2009000654A MX2009000654A MX2009000654A MX 2009000654 A MX2009000654 A MX 2009000654A MX 2009000654 A MX2009000654 A MX 2009000654A MX 2009000654 A MX2009000654 A MX 2009000654A MX 2009000654 A MX2009000654 A MX 2009000654A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- nucleotide positions
- nucleotide
- stretch
- positions
- Prior art date
Links
- 101710092490 Protein kinase 3 Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 29
- 125000003729 nucleotide group Chemical group 0.000 abstract 29
- 230000000295 complement effect Effects 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
La presente invención se refiere a una molécula de ácido nucleico que comprende una estructura de doble cadena, en donde la estructura de doble cadena comprende una primera cadena y una segunda cadena, en donde la primera cadena comprende un primer estiramiento de nucleótidos contiguos, y este primer estiramiento es cuando menos parcialmente complementario a un ácido nucleico objetivo, y en donde la segunda cadena comprende un segundo estiramiento de nucleótidos contiguos, y este segundo estiramiento es cuando menos parcialmente complementario para el primer estiramiento, en donde el primer estiramiento comprende una secuencia de ácido nucleico que es cuando menos parcialmente complementaria para una secuencia de nucleótidos de núcleo de la secuencia de ácido nucleico de acuerdo con la SEQ ID NO:1 (NM_013355), o parte de la misma, en donde la secuencia de nucleótidos de núcleo comprende la secuencia de nucleótidos de las posiciones 482 a 500 de la SEQ ID NO:1 (SEQ ID NO:2); de las posiciones de nucleótidos 1555 a 1573 de la SEQ ID NO:1 (SEQ ID NO:4); de las posiciones de nucleótidos 1556 a 1574 de la SEQ ID NO:1 (SEQ ID NO:6); de las posiciones de nucleótidos 1559 a 1577 de la SEQ ID NO:1(SEQ ID NO:8); de las posiciones de nucleótidos 1566 a 1584 de la SEQ ID NO:1 (SEQ ID NO:10); de las posiciones de nucleótidos 2094 a 2112 de la SEQ ID NO:1 (SEQ ID NO:12); de las posiciones de nucleótidos 2102 a 2120 de la SEQ ID NO:1 (SEQ ID NO:14); de las posiciones de nucleótidos 2286 a 2304 de la SEQ ID NO:1 (SEQ ID NO:16); de las posiciones de nucleótidos 2761 a 2779 de la SEQ ID NO:1 (SEQ ID NO:18); de las posiciones de nucleótidos 2763 a 2781 de la SEQ ID NO:1 (SEQ ID NO:20); de las posiciones de nucleótidos 2764 a 2782 de la SEQ ID NO:1 (SEQ ID NO:22); de las posiciones de nucleótidos 2843 a 2861 de la SEQ ID NO:1 (SEQ ID NO:24); de las posiciones de nucleótidos 2844 a 2862 de la SEQ ID NO:1 (SEQ ID NO:26); o de las posiciones de nucleótidos 2846 a 2864 de la SEQ ID NO:1 (SEQ ID NO:28); de preferencia, la secuencia de nucleótidos de núcleo comprende la secuencia de nucleótidos de las posiciones de nucleótidos 1555 a 1573 de la SEQ ID NO:1 (SEQ ID NO:4); de las posiciones de nucleótidos 1556 a 1574 de la SEQ ID NO:1 (SEQ ID NO:6); de las posiciones de nucleótidos 1559 a 1577 de la SEQ ID NO:1 (SEQ ID NO:8); de las posiciones de nucleótidos 1566 a 1584 de la SEQ ID NO:1 (SEQ ID NO:10); de las posiciones de nucleótidos 2094 a 2112 de la SEQ ID NO:1 (SEQ ID NO:12); o de las posiciones de nucleótidos 2286 a 2304 de la SEQ ID NO:1 (SEQ ID NO:16); en donde, de preferencia, el primer estiramiento es adicionalmente cuando menos parcialmente complementario para una región precedente al extremo 5' de la secuencia de nucleótidos de núcleo y/o para una región siguiente al extremo 3' de la secuencia de nucleótidos de núcleo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06015262 | 2006-07-21 | ||
| PCT/EP2007/006492 WO2008009477A2 (en) | 2006-07-21 | 2007-07-20 | Means for inhibiting the expression of protein kinase 3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009000654A true MX2009000654A (es) | 2009-07-22 |
Family
ID=38663298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009000654A MX2009000654A (es) | 2006-07-21 | 2007-07-20 | Medios para inhibir la expresion de la cinasa de proteina 3. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8232256B2 (es) |
| EP (2) | EP2049658A2 (es) |
| JP (3) | JP2009544281A (es) |
| KR (1) | KR101670085B1 (es) |
| CN (3) | CN101490253A (es) |
| AU (1) | AU2007276388A1 (es) |
| BR (1) | BRPI0714875A2 (es) |
| CA (1) | CA2658550C (es) |
| HK (1) | HK1208701A1 (es) |
| MX (1) | MX2009000654A (es) |
| RU (1) | RU2553561C2 (es) |
| WO (1) | WO2008009477A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040052840A1 (en) * | 2000-06-20 | 2004-03-18 | Shunichiro Kubota | Preparations for oligonucleotide transfer |
| KR100888566B1 (ko) * | 2001-06-20 | 2009-03-12 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 핵산 도입을 촉진시키는 방법 |
| IL166718A0 (en) | 2002-08-14 | 2006-01-15 | Atugen Ag | Further use of protein kinase n beta |
| ES2548515T3 (es) | 2004-12-27 | 2015-10-19 | Silence Therapeutics Gmbh | Complejos lipídicos recubiertos con PEG y su uso |
| JP2009544281A (ja) | 2006-07-21 | 2009-12-17 | サイレンス・セラピューティクス・アーゲー | プロテインキナーゼ３の発現を阻害するための手段 |
| WO2010110314A1 (ja) * | 2009-03-27 | 2010-09-30 | 協和発酵キリン株式会社 | 核酸を含有する肺高血圧症治療剤 |
| EP2382994A1 (en) * | 2010-04-26 | 2011-11-02 | Maurizio Victor Cattaneo | Ligand targeted nanocapsules for the delivery of RNAi and other agents |
| WO2013170960A1 (en) | 2012-05-16 | 2013-11-21 | Silence Therapeutics Ag | Use of vegfr1 as a biomarker for pkn3 inhibitor administration |
| WO2016083623A1 (en) * | 2014-11-28 | 2016-06-02 | Silence Therapeutics Gmbh | Means for the treatment of pre-eclampsia |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| RU2698199C1 (ru) * | 2018-05-18 | 2019-08-23 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт общей патологии и патофизиологии" | Средство для подавления экспрессии генов, связанных с накоплением холестерина макрофагами человека |
| CN120682233B (zh) * | 2025-08-25 | 2025-12-12 | 浙江大学 | Pkn3激酶抑制剂、药物组合物及pkn3激酶抑制剂的制备方法和应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| CA2126691C (en) | 1991-12-24 | 2003-05-06 | Phillip Dan Cook | Gapped 2' modified oligonucleotides |
| JPH07509133A (ja) | 1992-07-17 | 1995-10-12 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 動物疾患の処置のための方法および剤 |
| US5504103A (en) * | 1993-08-25 | 1996-04-02 | Eli Lilly And Company | Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof |
| US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| CA2227373A1 (en) | 1995-07-21 | 1997-02-06 | Promega Biosciences, Inc. | Novel amide-based cationic lipids |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| CA2217550A1 (en) | 1996-10-22 | 1998-04-22 | F. Hoffmann-La Roche Ag | Cationic lipids for gene therapy |
| US6358523B1 (en) * | 1996-12-06 | 2002-03-19 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and regulating |
| US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
| CA2286739A1 (en) | 1997-04-04 | 1998-10-15 | Jinkang Wang | Improved methods of delivery using cationic lipids and helper lipids |
| WO1998051285A2 (en) | 1997-05-15 | 1998-11-19 | Genzyme Corporation | Cationic amphiphile formulations |
| US20030073640A1 (en) * | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| AU8525098A (en) | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP1038016A2 (en) | 1997-12-16 | 2000-09-27 | Valentis Inc. | Needle-free injection of formulated nucleic acid molecules |
| CA2326823A1 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| US6150345A (en) * | 1998-08-10 | 2000-11-21 | Regents Of The University Of California | Methods for promoting survival of myelin producing cells |
| FR2788275B1 (fr) * | 1999-01-11 | 2002-06-14 | Lipha | ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7015040B2 (en) * | 1999-02-26 | 2006-03-21 | Mirus Bio Corporation | Intravascular delivery of nucleic acid |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| JP2003501038A (ja) | 1999-05-28 | 2003-01-14 | スージェン・インコーポレーテッド | 蛋白質キナーゼ |
| EP1064944A1 (en) | 1999-06-25 | 2001-01-03 | Schering Aktiengesellschaft | Protein kinase N inhibitor comprising Fasudil |
| ES2235916T3 (es) | 1999-07-15 | 2005-07-16 | Inex Pharmaceuticals Corp. | Preparacion de agentes terapeuticos de encapsulacion lipidica. |
| US6133032A (en) * | 1999-09-09 | 2000-10-17 | Isis Pharmaceutical Inc. | Antisense modulation of PI3 kinase p110 beta expression |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| MXPA02009069A (es) | 2000-03-17 | 2004-04-05 | Benitec Australia Ltd | Silenciamiento genetico. |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| WO2001080900A2 (en) | 2000-04-20 | 2001-11-01 | The University Of British Columbia | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane |
| ATE354350T1 (de) | 2000-10-25 | 2007-03-15 | Univ British Columbia | Lipidformulierungen zur zielgerichteten abgabe |
| DE60130583T3 (de) | 2000-12-01 | 2018-03-22 | Europäisches Laboratorium für Molekularbiologie | Kleine rns moleküle, die rns-interferenz vermitteln |
| US6394713B1 (en) * | 2001-03-05 | 2002-05-28 | Phillip E. Yates, Sr. | Drill guide apparatus |
| WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20030135033A1 (en) * | 2002-01-04 | 2003-07-17 | Anke Klippel-Giese | Compounds and methods for the identification and/ or validation of a target |
| GB2397062B (en) | 2002-02-20 | 2005-06-15 | Sirna Therapeutics Inc | RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA) |
| CN100543137C (zh) | 2002-08-05 | 2009-09-23 | 阿图根股份公司 | 其它新形式的干扰rna分子 |
| PT1857547T (pt) * | 2002-08-05 | 2018-02-08 | Silence Therapeutics Gmbh | Formas adicionais novas de moléculas de rna de interferência |
| AU2003258075A1 (en) | 2002-08-06 | 2004-02-23 | Lyotropic Therapeutics, Inc. | Lipid-drug complexes in reversed liquid and liquid crystalline phases |
| EP1393742A1 (en) | 2002-08-14 | 2004-03-03 | atugen AG | Use of protein kinase N beta |
| IL166718A0 (en) | 2002-08-14 | 2006-01-15 | Atugen Ag | Further use of protein kinase n beta |
| US7635770B2 (en) * | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
| ES2321841T3 (es) * | 2003-08-26 | 2009-06-12 | Smithkline Beecham Corporation | Copolimeros heterofuncionales de glicerol y polietilenglicol, sus conjugados y composiciones. |
| CN102940891B (zh) | 2004-05-05 | 2016-02-24 | 赛伦斯治疗有限公司 | 脂质、脂质复合物及其应用 |
| AU2005306075A1 (en) | 2004-11-19 | 2006-05-26 | Novosom Ag | Improvements in or relating to pharmaceutical compositions for local administration |
| ES2548515T3 (es) * | 2004-12-27 | 2015-10-19 | Silence Therapeutics Gmbh | Complejos lipídicos recubiertos con PEG y su uso |
| WO2006074546A1 (en) | 2005-01-13 | 2006-07-20 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| JP2009544281A (ja) | 2006-07-21 | 2009-12-17 | サイレンス・セラピューティクス・アーゲー | プロテインキナーゼ３の発現を阻害するための手段 |
| RU2360967C1 (ru) * | 2007-10-01 | 2009-07-10 | Химический факультет Московского государственного университета имени М.В.Ломоносова | Биокатализатор на основе иммобилизованных клеток бактерий для разложения метилфосфоновой кислоты и ее эфиров |
-
2007
- 2007-07-20 JP JP2009519879A patent/JP2009544281A/ja active Pending
- 2007-07-20 EP EP07786240A patent/EP2049658A2/en not_active Withdrawn
- 2007-07-20 AU AU2007276388A patent/AU2007276388A1/en not_active Abandoned
- 2007-07-20 KR KR1020097000738A patent/KR101670085B1/ko not_active Expired - Fee Related
- 2007-07-20 CN CNA200780026982XA patent/CN101490253A/zh active Pending
- 2007-07-20 BR BRPI0714875-5A patent/BRPI0714875A2/pt not_active Application Discontinuation
- 2007-07-20 EP EP12005028A patent/EP2546337A1/en not_active Withdrawn
- 2007-07-20 MX MX2009000654A patent/MX2009000654A/es active IP Right Grant
- 2007-07-20 RU RU2009106071/10A patent/RU2553561C2/ru not_active IP Right Cessation
- 2007-07-20 CN CN201410643357.1A patent/CN104531701A/zh active Pending
- 2007-07-20 US US12/307,052 patent/US8232256B2/en not_active Expired - Fee Related
- 2007-07-20 WO PCT/EP2007/006492 patent/WO2008009477A2/en not_active Ceased
- 2007-07-20 CN CN201110188043.3A patent/CN102321626B/zh not_active Expired - Fee Related
- 2007-07-20 CA CA2658550A patent/CA2658550C/en not_active Expired - Fee Related
-
2013
- 2013-02-25 JP JP2013034653A patent/JP2013172714A/ja not_active Ceased
-
2015
- 2015-02-19 JP JP2015030813A patent/JP2015128433A/ja active Pending
- 2015-09-17 HK HK15109144.9A patent/HK1208701A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2658550C (en) | 2018-06-19 |
| CN101490253A (zh) | 2009-07-22 |
| JP2009544281A (ja) | 2009-12-17 |
| CN104531701A (zh) | 2015-04-22 |
| AU2007276388A1 (en) | 2008-01-24 |
| CN102321626B (zh) | 2014-12-10 |
| RU2009106071A (ru) | 2010-08-27 |
| CA2658550A1 (en) | 2008-01-24 |
| EP2546337A1 (en) | 2013-01-16 |
| US20090304678A1 (en) | 2009-12-10 |
| JP2013172714A (ja) | 2013-09-05 |
| EP2049658A2 (en) | 2009-04-22 |
| KR20090039715A (ko) | 2009-04-22 |
| JP2015128433A (ja) | 2015-07-16 |
| RU2553561C2 (ru) | 2015-06-20 |
| US8232256B2 (en) | 2012-07-31 |
| BRPI0714875A2 (pt) | 2013-05-28 |
| WO2008009477A3 (en) | 2008-05-29 |
| HK1208701A1 (en) | 2016-03-11 |
| CN102321626A (zh) | 2012-01-18 |
| WO2008009477A2 (en) | 2008-01-24 |
| KR101670085B1 (ko) | 2016-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009000654A (es) | Medios para inhibir la expresion de la cinasa de proteina 3. | |
| Law et al. | Establishing, maintaining and modifying DNA methylation patterns in plants and animals | |
| WO2007051045A3 (en) | Compositions and methods for inhibiting expression of huntingtin gene | |
| WO2007056326A3 (en) | Compositions and methods for inhibiting expression of nav1.8 gene | |
| WO2008036933A3 (en) | Compositions and methods for inhibiting expression of the hamp gene | |
| WO2011056005A3 (ko) | 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도 | |
| MX346862B (es) | Secuencias consenso de envoltura de vih y método para usar las mismas. | |
| MX2009000656A (es) | Acidos nucleicos que se fijan a sdf-i. | |
| WO2008005562A3 (en) | Rna silencing compositions and methods for the treatment of huntington's disease | |
| EP2021507A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING PCSK9 GENE EXPRESSION | |
| WO2008008719A3 (en) | Compositions and methods for inhibiting expression of the myc gene | |
| WO2001077375A3 (en) | Diagnosis of diseases associated with gene regulation | |
| AU2008339215A8 (en) | Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof | |
| WO2007087451A3 (en) | Compositions and methods for enhancing discriminatory rna interference | |
| WO2008116860A3 (en) | Dsrna compositions and methods for treating hpv infections | |
| WO2009054551A3 (en) | Lipid-modified double-stranded rna having potent rna interference effect | |
| WO2009035303A3 (en) | Bacteriophage or lytic protein derived from the bacteriophage which effective for treatment of staphylococcus aureus biofilm | |
| WO2008109142A3 (en) | Pirna and uses related thereto | |
| MX337801B (es) | Acidos nucleicos que se enlazan on mcp-1. | |
| WO2010006973A3 (en) | Compositions and methods for inhibiting expression of tgf-beta receptor genes | |
| WO2007127919A3 (en) | Compositions and methods for inhibiting expression of a gene from the jc virus | |
| WO2009040113A3 (en) | C5a BINDING NUCLEIC ACIDS | |
| WO2006032041A3 (en) | Compositions and methods for inhibiting expression of anti-apoptotic genes | |
| NZ604094A (en) | Double stranded rna compounds to rhoa and use thereof | |
| WO2007137220A3 (en) | Compositions and methods for inhibiting expression of ikk-b gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |